Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance

Archive ouverte

Laurent, Camille | Trisal, Preeti | Tesson, Bruno | Seth, Sahil | Beyou, Alicia | Roulland, Sandrine | Lesne, Bastien | van Acker, Nathalie | Cerapio, Juan Pablo | Chartier, Loïc | Guille, Arnaud | Stokes, Matthew | Huang, Chris | Huet, Sarah | Gandhi, Anita Krithivas | Morschhauser, Franck | Xerri, Luc

Edité par CCSD ; American Society of Hematology -

International audience. A robust prognostic and biological classification for newly diagnosed follicular lymphoma (FL) using molecular profiling remains challenging. FL tumors from patients treated in the RELEVANCE trial with rituximab-chemotherapy (R-chemo) or rituximab-lenalidomide (R2) were analyzed using RNA-sequencing, DNA-sequencing, immunohistochemistry (IHC) and/or fluorescence in situ hybridization. Unsupervised gene clustering identified two gene expression signatures (GS) enriched with normal memory (MEM) B-cells and germinal center (GC) B-cells signals, respectively. These two GS were combined into a 20-genes predictor (FL20) to classify patients into MEM-like (n=160) or GC-like (n=164) subtypes, which also displayed different mutational profiles. In the R-chemo arm, MEM-like patients had significantly shorter progression free survival (PFS) than GC-like patients (HR=2.13; p=0.0023), and this prognostic correlation remained significant in a multivariable model including FLIPI (p=0.005). In the R2 arm, both subtypes had comparable PFS, demonstrating a R2 benefit over R-chemo for MEM-like patients (HR=0.54; p=0.011). The prognostic value of FL20 was validated in an independent FL cohort with R-chemo treatment (GSE119214 (n=137)). An IHC algorithm (FLCM) using FOXP1, LMO2, CD22 and MUM1 antibodies was developed with significant prognostic correlation with FL20 in a training set of RELEVANCE (n=264) patients, which was then validated in a different set of patients (n=116). These data indicate that FL tumors can be classified into MEM-like and GC-like subtypes that are biologically distinct and clinically different in risk profile. The FLCM assay can be used in routine clinical practice to identify MEM-like FL patients who might benefit from therapies other than R-chemo, such as the R2 combination. ClinicalTrials.gov identifier: RELEVANCE: NCT01476787 and NCT01650701 INTRODUCTION

Suggestions

Du même auteur

BIOMARKERS AND METHODS OF TREATMENT OF FOLLICULAR LYMPHOMA

Archive ouverte | Huang Chong, Chris | CCSD

Provided herein are methods and kits of using certain biomarkers in identifying subtypes of follicular lymphoma, selectively treating the subtypes of follicular lymphoma (FL), and identifying a subject who is likely to be responsi...

Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen.

Archive ouverte | Laurent, Camille | CCSD

International audience

High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B

Archive ouverte | Laurent, Camille | CCSD

International audience. Although follicular lymphoma (FL) is usually graded as FL1-2, FL3A, and FL3B, some borderline cases can be observed and led us to investigate the clinicopathologic diversity of grade 3 FL (FL...

Chargement des enrichissements...